IMS Company Profiles - Report Buyer

IMS Company Profiles - Report Buyer IMS Company Profiles - Report Buyer

reportbuyer.com
from reportbuyer.com More from this publisher
06.03.2013 Views

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING Sub sid iary of: Sandoz, Aus tria Phar ma ceu ti cal Sales: US$ 4-5 mil lion Prod ucts (% of Sales by Lead ing 5): 80-85% Ther a peu tic Classes (% of Sales by Lead ing 5): 85-90% Dose Forms (% of Sales by Lead ing 5): 95-100% Prin ci pal Prod ucts: LINEX (antidiarrheal mi cro-or gan ism) AMOKSIKLAV 2X (pen i cil lin broad spec trum) BRONCHO MUNAL (vac cine other) FERRUM LEK (iron plain/com bi na tion) EDICIN (an ti bac te rial other) Ther a peu tic Range: antidiarrheals, elec tro lyte re plac ers, in tes ti nal anti-inflammatorie s 37% antibacterials sys temic 31% vac cines 8% antianemic prep a ra tions 8% psycholeptics 4% Lead ing Dose Forms: cap sules 49% tab lets 23% coated tab lets 14% liq uids 7% in fu sions 4% NOVARTIS Full Name: Novartis Pharma Ser vices AG, Rep re - sen ta tive & Re gional Of fice Street Ad dress: Brivibas gatve 214b, 302 kab., LV-1039 Riga Tel: +371 6 788 7070 Fax: +371 6 788 7077 Home Page: www.mea.novartis.com Phar ma ceu ti cal Sales: US$ 4-5 mil lion Prod ucts (% of Sales by Lead ing 5): 55-60% Ther a peu tic Classes (% of Sales by Lead ing 5): 65-70% Dose Forms (% of Sales by Lead ing 5): 90-95% Prin ci pal Prod ucts: GLIVEC (antineoplastic other) SANDOSTATIN LAR (hor mone hy po tha lamic) LEPONEX (antipsychotic) FEMARA (cytostatic hor mone an tag o nist) SANDIMMUN NEORAL (immunosuppressive agent) Ther a peu tic Range: antineoplastics 24% immunosuppressive agents 15% hor mones pi tu itary and hy po tha lamic 13% psycholeptics 9% cytostatic hor mone ther apy 7% Lead ing Dose Forms: tab lets 45% coated tab lets 13% vi als 13% cap sules 11% in fu sions 10% NOVARTIS CON SUMER HEALTH Full Name: Novartis Con sumer Health Ser vices SA Street Ad dress: Kleistu 24, LV-1067 Riga Tel: +371 6 744 1300 Fax: +371 6 744 1301 De scrip tion: Rep re sen ta tive of fice. Pro moter. Prod uct ranges in clude: phar ma ceu ti cal prod ucts (branded, non-pre scrip tion), med i cal equip ment. Es tab lished 1997. 7 phar ma ceu ti cal employees in 2008. Rep re sen ta tives/De tail ers (Pharm, Num - ber): 1-10 (2008) Con tacts (Pharm): Chair man: Bjarne Pedersen; Gen eral Con tact: Atvars Kurats Phar ma ceu ti cal Sales: US$ 4-5 mil lion Prod ucts (% of Sales by Lead ing 5): 55-60% Ther a peu tic Classes (% of Sales by Lead ing 5): 85-90% Dose Forms (% of Sales by Lead ing 5): 90-95% Prin ci pal Prod ucts: THERAFLU NON-DROWS (cold prep a ra tion with - out anti-in fec tive) TAVEGYL (an ti his ta mine sys temic) THERAFLU NIGHT TIM (cold prep a ra tion with out anti-in fec tive) VIBROCIL (na sal prep a ra tion top i cal) OTRIVIN (na sal prep a ra tion top i cal) Ther a peu tic Range: cough and cold prep a ra tions 36% na sal prep a ra tions 22% an ti his ta mines sys temic 12% dermatological antifungals 9% antivaricosis/antihemorrhoidal prep a ra tions 9% Lead ing Dose Forms: pow ders/gran ules 34% liq uids 27% tab lets 13% gels/sols 10% creams 8% © 2009 IMS Health In cor po rated or its af fil i ates Page 184

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING LEBANON NOVARTIS Full Name: Novartis Pharma Ser vices AG, Bei rut Rep re sen ta tive Of fice Postal Ad dress: PO Box 11-3448, Bei rut Street Ad dress: Weav ers Cen ter, 7th Floor, Clemenceau Street, Bei rut Tel: +961 1 363260 Fax: +961 1 371567 Home Page: www.mea.novartis.com Phar ma ceu ti cal Sales: US$ 14-16 mil lion Prod ucts (% of Sales by Lead ing 5): 45-50% Ther a peu tic Classes (% of Sales by Lead ing 5): 60-65% Dose Forms (% of Sales by Lead ing 5): 90-95% Prin ci pal Prod ucts: CO DIOVAN (an gio ten sin-II an tag o nist com bi na - tion) DIOVAN (an gio ten sin-II an tag o nist plain) LESCOL (cho les terol/triglyceride reg u lat ing prep - a ra tion) FEMARA (cytostatic hor mone an tag o nist) TEGRETOL (antiepileptic) Ther a peu tic Range: renin-an gio ten sin sys tem agents 27% lipid-reg u lat ing/antiatheroma prep a ra tions 10% ophthalmologicals 9% cytostatic hor mone ther apy 7% anti rheu ma tics sys temic 7% Lead ing Dose Forms: coated tab lets 31% tab lets 31% cap sules 20% liq uids 10% sup pos i to ries 3% SANDOZ Full Name: Sandoz GmbH, Bei rut Rep re sen ta tive Of fice Postal Ad dress: PO Box 90-1599, Bei rut Street Ad dress: Horsh Kfoury, Badaro, Noueihed Bldg. 6th floor, Bei rut Tel: +961 1 382 490 Fax: +961 1 382 492 Email: sandoz@sandoz-lb.com Home Page: sandoz-lb.com De scrip tion: Rep re sen ta tive of fice. Pro moter. Prod uct ranges in clude: phar ma ceu ti cal prod ucts (branded, pre scrip tion, non-pre scrip tion). Es tab - lished 1998. 18 phar ma ceu ti cal employees in 2008. Rep re sen ta tives/De tail ers (Pharm, Num - ber): 12 (2008) Con tacts (Pharm): Chair man: Abir Alaeddine; Com mer cial Op er a tions: Reina Tannous, Hisham Joudieh; Gen eral Con tact: Chantal Ghawi Phar ma ceu ti cal Sales: US$ 2-3 mil lion Prod ucts (% of Sales by Lead ing 5): 75-80% Ther a peu tic Classes (% of Sales by Lead ing 5): 95-100% Dose Forms (% of Sales by Lead ing 5): 95-100% Prin ci pal Prod ucts: CURAM (pen i cil lin broad spec trum) OSPAMOX (pen i cil lin broad spec trum) OSPEN (pen i cil lin me dium/nar row spec trum) BIODROXIL (cephalosporin) SUPPLIN (amebicide) Ther a peu tic Range: antibacterials sys temic 82% antiparasitics 7% an ti bi ot ics, sulphonamides and antivirals top i cal 5% lipid-reg u lat ing/antiatheroma prep a ra tions 3% dermatological antifungals 2% Lead ing Dose Forms: coated tab lets 34% tab lets 30% liq uids 17% cap sules 12% oint ments 4% LITHUANIA HEXAL Full Name: Hexal AG, Co op er a tion Part ner/Rep - re sen ta tive Of fice Lith u a nia Street Ad dress: Zemaitijos g. 3-16, LT-01134 Vilnius Tel: +370 52 61 31 06/30 63 Fax: +370 52 61 30 66 Email: hexal@takas.lt Home Page: www.hexal.lt De scrip tion: Im porter, dis trib u tor, pro moter, sales/detailer. Prod uct ranges in clude: phar ma - ceu ti cal prod ucts (branded, unbranded, pre scrip - tion, non-pre scrip tion), hos pi tal pharmaceuticals, med i cal equip ment, oph thal mic prod ucts. Established 1996. Con tacts (Pharm): Gen eral Con tact: Tauras Endriukaitis © 2009 IMS Health In cor po rated or its af fil i ates Page 185

<strong>IMS</strong> COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING<br />

LEBANON<br />

NOVARTIS<br />

Full Name: Novartis Pharma Ser vices AG, Bei rut<br />

Rep re sen ta tive Of fice<br />

Postal Ad dress: PO Box 11-3448, Bei rut<br />

Street Ad dress: Weav ers Cen ter, 7th Floor,<br />

Clemenceau Street, Bei rut<br />

Tel: +961 1 363260<br />

Fax: +961 1 371567<br />

Home Page: www.mea.novartis.com<br />

Phar ma ceu ti cal Sales: US$ 14-16 mil lion<br />

Prod ucts (% of Sales by Lead ing 5): 45-50%<br />

Ther a peu tic Classes (% of Sales by Lead ing<br />

5): 60-65%<br />

Dose Forms (% of Sales by Lead ing 5):<br />

90-95%<br />

Prin ci pal Prod ucts:<br />

CO DIOVAN (an gio ten sin-II an tag o nist com bi na -<br />

tion)<br />

DIOVAN (an gio ten sin-II an tag o nist plain)<br />

LESCOL (cho les terol/triglyceride reg u lat ing prep -<br />

a ra tion)<br />

FEMARA (cytostatic hor mone an tag o nist)<br />

TEGRETOL (antiepileptic)<br />

Ther a peu tic Range:<br />

renin-an gio ten sin sys tem agents 27%<br />

lipid-reg u lat ing/antiatheroma prep a ra tions<br />

10%<br />

ophthalmologicals 9%<br />

cytostatic hor mone ther apy 7%<br />

anti rheu ma tics sys temic 7%<br />

Lead ing Dose Forms:<br />

coated tab lets 31%<br />

tab lets 31%<br />

cap sules 20%<br />

liq uids 10%<br />

sup pos i to ries 3%<br />

SANDOZ<br />

Full Name: Sandoz GmbH, Bei rut Rep re sen ta tive<br />

Of fice<br />

Postal Ad dress: PO Box 90-1599, Bei rut<br />

Street Ad dress: Horsh Kfoury, Badaro,<br />

Noueihed Bldg. 6th floor, Bei rut<br />

Tel: +961 1 382 490<br />

Fax: +961 1 382 492<br />

Email: sandoz@sandoz-lb.com<br />

Home Page: sandoz-lb.com<br />

De scrip tion: Rep re sen ta tive of fice. Pro moter.<br />

Prod uct ranges in clude: phar ma ceu ti cal prod ucts<br />

(branded, pre scrip tion, non-pre scrip tion). Es tab -<br />

lished 1998. 18 phar ma ceu ti cal employees in<br />

2008.<br />

Rep re sen ta tives/De tail ers (Pharm, Num -<br />

ber): 12 (2008)<br />

Con tacts (Pharm): Chair man: Abir Alaeddine;<br />

Com mer cial Op er a tions: Reina Tannous, Hisham<br />

Joudieh; Gen eral Con tact: Chantal Ghawi<br />

Phar ma ceu ti cal Sales: US$ 2-3 mil lion<br />

Prod ucts (% of Sales by Lead ing 5): 75-80%<br />

Ther a peu tic Classes (% of Sales by Lead ing<br />

5): 95-100%<br />

Dose Forms (% of Sales by Lead ing 5):<br />

95-100%<br />

Prin ci pal Prod ucts:<br />

CURAM (pen i cil lin broad spec trum)<br />

OSPAMOX (pen i cil lin broad spec trum)<br />

OSPEN (pen i cil lin me dium/nar row spec trum)<br />

BIODROXIL (cephalosporin)<br />

SUPPLIN (amebicide)<br />

Ther a peu tic Range:<br />

antibacterials sys temic 82%<br />

antiparasitics 7%<br />

an ti bi ot ics, sulphonamides and antivirals top i cal<br />

5%<br />

lipid-reg u lat ing/antiatheroma prep a ra tions 3%<br />

dermatological antifungals 2%<br />

Lead ing Dose Forms:<br />

coated tab lets 34%<br />

tab lets 30%<br />

liq uids 17%<br />

cap sules 12%<br />

oint ments 4%<br />

LITHUANIA<br />

HEXAL<br />

Full Name: Hexal AG, Co op er a tion Part ner/Rep -<br />

re sen ta tive Of fice Lith u a nia<br />

Street Ad dress: Zemaitijos g. 3-16, LT-01134<br />

Vilnius<br />

Tel: +370 52 61 31 06/30 63<br />

Fax: +370 52 61 30 66<br />

Email: hexal@takas.lt<br />

Home Page: www.hexal.lt<br />

De scrip tion: Im porter, dis trib u tor, pro moter,<br />

sales/detailer. Prod uct ranges in clude: phar ma -<br />

ceu ti cal prod ucts (branded, unbranded, pre scrip -<br />

tion, non-pre scrip tion), hos pi tal pharmaceuticals,<br />

med i cal equip ment, oph thal mic prod ucts.<br />

Established 1996.<br />

Con tacts (Pharm): Gen eral Con tact: Tauras<br />

Endriukaitis<br />

© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 185

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!